Spero

Seres Therapeutics’ oral microbiome treatment for C. difficile infections (CDI) proved superior to placebo in reducing CDI recurrence, according to Phase 3 data published last week in the New England Journal of Medicine. Touting the “first-ever positive pivotal clinical results for a targeted microbiome drug,” the Massachusetts-based company said in a press release it would finalize its U.S. FDA Biologics License Application for SER-109 in mid-2022.

The treatment boasts FDA…

Massachusetts-based Spero Therapeutics announced last week that the U.S. FDA has approved its oral antimicrobial SPR720 to start Phase 2a trials in people with non-TB mycobacterial (NTM) pulmonary disease from M. avium complex.

Spero and the Gates Medical Research Institute are also evaluating SPR720 as a treatment for M. tuberculosis in low- and middle-income countries.

Mentions:

Multiple organizations announced investments in tackling antibiotic resistance over the past week.

First, the U.S. Department of Health and Human Services announced last week that its Biomedical Advanced Research and Development Authority will give up to $20.7 million over two years to Pennsylvania’s VenatoRx to share costs needed to bring to market a novel antibiotic for drug-resistant infections, with the option to extend the contract to a total cost-share of $86.8 million over six…